ImmunoPrecise Antibodies (NASDAQ:IPA) Issues Quarterly Earnings Results

ImmunoPrecise Antibodies (NASDAQ:IPA) released its quarterly earnings data on Friday. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.06), Zacks reports. The firm had revenue of $4.23 million for the quarter, compared to analysts’ expectations of $6.59 million. ImmunoPrecise Antibodies had a negative net margin of 114.50% and a negative return on equity of 73.74%.

ImmunoPrecise Antibodies Price Performance

Shares of NASDAQ IPA opened at $0.39 on Friday. ImmunoPrecise Antibodies has a 1 year low of $0.27 and a 1 year high of $1.59. The stock has a market capitalization of $12.18 million, a P/E ratio of -0.50 and a beta of 0.09. The company’s 50-day moving average is $0.44 and its 200 day moving average is $0.48. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.01 and a quick ratio of 0.85.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of ImmunoPrecise Antibodies in a research report on Friday, March 14th.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.